The Pharmacokinetics of Cefuroxime in Man in Relation to its Antibacterial Activity by Dr Cynthia H O'Callaghan and Dr S M Harding (Glaxo Research Ltd, Greenford, Middlesex, UK) Successful treatment of any bacterial infection depends partly on the therapeutic agent possessing good activity against the infecting organism but also on its ability to spread rapidly and widely through the body of the host. It must remain in contact with the infecting bacteria long enough to inhibit them and not be hindered in this by excessive protein binding, metabolic destruction by either host or the infecting organisms, or by very rapid excretion from the body. The properties of cefuroxime have been shown to be favourable from many of these aspects , Foord 1976 .
In determining the human pharmacokinetics of cefuroxime, Foord used a form of cefuroxime sodium which rea,dily produced a solution, but this has now been replaced by a more crystalline form which gives a suspension when used in volumes acceptable for intramuscular injection. A volunteer study was therefore carried out to compare the pharmacokinetics of both forms after intramuscular administration.
As cefuroxime very effectively protected laboratory animals against a wide variety of experimental infections, the serum levels produced by its median effective dose (ED50) in rats and mice have been related to its minimum inhibitory concentrations (MICs) against the challenge organisms. Comparisons between the animal serum levels and the serum levels in man could then be useful in determining the therapeutic potential of the compound. Serum levels obtained in volunteers from the doses most appropriate to the clinical situation (750 mg and 1500 mg) were related to the MICs of cefuroxime for organisms commonly found to be pathogenic in wound, urinary tract, respiratory and gonococcal infections. Table 1 METHODS Drugs and Routes ofAdministration Cefuroxime was provided as the sodium salt to which water for injections was added. All nominal doses refer to the content of cefuroximne acid in the injection and, unless stated, the suspension presentation has been used. Vials of cefuroxime containing the precise amounts of cefuroxime acid were used in the solution/suspension comparison. This was found to give rise to about 10 % loss of material in drawing up the drug, so overages to the vials, enabling the full dose to be removed, were added for subsequent studies.
Intramuscular (i.m.) injection volumes ranged from 2.1 ml (500 mg suspension) to 5.5 ml (1000 mg solution). The 1500 mg i.m. dose was given as 2 x 750 mg doses. All i.m. injections were given into the thigh using a 1.5 inch (3.8 cm) 21-gauge needle. The intravenous (i.v.) doses were prepared as solutions by adding water to give 10 ml (750 mg) and 20 ml (1500 mg). These injections were given via the antecubital vein as a bolus over 5-10 sec.
Volunteers and Trial Design
Volunteers were male members of Glaxo staff and followed a fairly normal daily routine at work throughout these trials. Most studies, however, involved the volunteers remaining in the laboratory for 2 h after dosing.
The solution and suspension preparations of cefuroxime were compared by giving them i.m. in 500 mg doses on weeks I and 2 and in 1000 mg doses on weeks 3 and 4 in cross-over fashion to 8 volunteers (age range 25-40 years, weights 59-91 kg, average 71 kg). The average blood level curve after 750 mg cefuroxime i.m. was constructed from data obtained from 12 volunteers (age range 19-44 years; weights 60-84 kg, average 71 kg) who received cefuroxime as part of two further studies. The 1500 mg i.m. dose was given as 750 mg into each thigh to 4 volunteers (average age 29 years, weight 65 kg). The 750 mg and 1500 mg doses i.v. were given to 2 groups of 3 volunteers (average ages 34 and 35 years, weights 69 and 78 kg).
Mean observed serum or plasma levels following i.m. injection of 500 and 1000 mg of cefuroxime sodium in solution and in suspension in 8 volunteers Collection ofSpecimensfor Antibiotic Assay phosphate buffer, and urine samples were diluted In all studies, winged needles were inserted for in the same buffer. Serum samples of low estiease of repeated blood sampling. The needle and mated concentration were assayed undiluted tubing were kept free of clots with 100 iu/ml against a serum standard. Otherwise, they were heparin. The timings of the samples are indicated diluted in M/20 phosphate buffer and assayed in Tables 1 and 3. Usually serum was separated against a buffer standard. Provided these samples from the blood and frozen for assay on the were diluted at least 1 in 4, serum protein did not following day. In the solution/suspension com-interfere with the assay. The results are expressed parison at 1000 mg dose, plasma was used and as cefuroxime acid. assay in plasma has been found to give the same result as assay in serum. Urines were usually Pharmacokinetic Analysis collected over the following time intervals: 0-1, Methods of analysis have been described pre-1-2, 2-4, 4-6, 6-12 and 12-24 h after dosing.
viously (Foord 1976) . A two-compartment, open system model was used and the computer-derived Assay ofCefuroxime constants were used to calculate various pharmaco-The currently preferred method of assaying kinetic parameters and to construct average cefuroxime uses a variant of Bacillis subtilis curves. In the 750 mg and 1500 mg i.m. and i.v. NCIB 3610 in Oxoid Antibiotic medium No. 2, studies (Tables 3 and 4) results have been with added 0.3 % sodium citrate, with a sensitivity corrected for body weight to 70 kg. Nonrange from 5 to 0.3 ,ug/ml. Standard solutions of parametric tests of significance (Wilcoxon signed cefuroxime sodium were prepared in pH 7 M/20 ranks test) have been applied where appropriate. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method, and the MIC in ug/ml was read after 18 h incubation at 37GC as the lowest concentration of cefuroxime which inhibited growth.
Animal Pharniacokinetics Serum samples were taken after subcutaneous injection of cefuroxime in mice and rats as described by Ryan et al. (1976) . Cefuroxime concentrations were determined by large plate microbiological assay.
RESULTS

Human Pharmacokinetic Studies using
Cefuroxime Suspensioni
The suspension of cefuroxime used in the volunteer studies contained approximately 22% w/v cefuroxime but, as the solubility of this form was Only 15 % w/v, about one-third of the dose remained undissolved. This fraction would be expected to dissolve readily in the body fluids after administration and indeed the results of the study comparing the solution and suspension forms support this assumption (Tables I and 2 , Fig 1) . Minor differences in the blood levels were within the limits of experimental error, although the slightly lower urinary recoveries and larger apparent volumes of distribution with the suspension (significant at the 500 mg dose) suggest that it has somewhat slower initial release from its site of injection. The cefuroxime suspension did not show the depot effect seen with penicillin suspensions, which are poorly soluble (0.02-0.5 % w/v). It has been shown in animals that cephalosporins with solubilities greater than 2 % w/v do not produce a depot effect (O'Callaghan, unpublished data).
The results of the studies performed with doses of 750 mg and 1500 mg are given in Tables 3 and 4 and in Figs 2 and 3. The blood levels and kinetic parameters from these experiments and from the 500 mg and 1000 mg doses were similar to those reported by Foord (1976) . However, the peak blood levels were lower in our studies. In the solution/suspension comparison this is partially explained by the volunteers receiving 10% less than the nominal doses. In addition, many factors affect blood levels after parenteral administration, even in healthy volunteers and indeed we have shown differences in the bioavailability of cefuroxime after injection into different muscle sites, in males and females, and with activity or rest after injection (Harding, unpublished data). Blood levels in patients may differ further because of disease, impaired renal function, or age.
In many of these instances, since the drug is metabolically stable, an increase occurs in the times the serum level exceeds the MICs of organisms likely to be treated. However, for the purposes of this paper, these times have been taken from the volunteer studies to give an indication of the relationship of the pharmacokinetics to the MICs of pathogenic organisms.
Relationship between Serutm Concentrations and Protective Effect in Experimental Aniimals
Cefuroxime was shown to protect mice and rats very effectively against a variety of experimental infections (Table 5 , adapted from Ryan et al. 1976 ). It was observed that a protecting effect could be obtained against some strains where cefuroxime appeared not to be highly active.
The mean serum levels of cefuroxime measured in rats and mice at doses similar to the ED50s are given in Table 6 . The antibiotic was rapidly absorbed from the site of injection and peak serum levels were recorded at 15 min after injection. They were closely dose-related. The concentrations fell rapidly after this and 2 h after injection the antibiotic was virtually undetectable in the serum. In several instances, particularly in the mouse, the peak serum levels produced by the ED50 dose did not reach the MIC of the challenge organisms. Even when such levels were achieved, they were not maintained.
Antibacterial Activity oJ Cefuroxime and its
Human Pharmacokinetics Relative to some Common Clinical Conditions (1) Organisms involved in infected wounds: These are mainly Staphylococcus aureus and Streptococcus pyogenes with Bacteroides fragilis now being recognized more frequently. Cefuroxime is highly active against the Streptococci. It is equally active against ,B-lactamase producing and non-enzyme producing strains of Staphylococcus autreus. Like other cephalosporins, however, it is much less active against those strains of Staphylococcus aureus which are methicillin resistant (Table 7) . It is active against non ,-lactamase producing strains of B. fragilis, but has much less activity when the organisms produce a /-lactamase. This enzyme is one of the few ,-lactamases to which cefuroxime is sensitive. The serum levels produced after injections of 750 mg of cefuroxime, either i.v. or i.m., exceeded the MICs of the Staphylococci and Streptococci for periods of more than 8 h. They exceeded the MICs for the non-enzyme producirrg strains of B. fragilis for about 5 h. Occasionally Pseudomonas aeruginosa is found in infected wounds, but cefuroxime has no activity against this organism.
(2) Urinary tract infections: The majority of isolates from this kind of infection are shown in Table 8 , together with the concentrations of cefuroxime to which 80 % are sensitive, and the times for which these values are exceeded in serum. The serum concentrations of cefuroxime exceeded the mean MICs for most of the organisms for periods of 3-4 h, but this period was much shorter for some of the indole-positive Proteus strains and the inhibitory concentration for Streptococcus fwecalis was not reached. The concentrations maintained in the urine greatly exceeded the MICs of all these organisms, for at least 8 h. Cefuroxime could thus be expected to have a good therapeutic effect in urinary tract infections.
(3) Respiratory infections and meninzgitis: The MICs of all the respiratory pathogens (apart from Klebsiella spp.) are exceeded for at least 8 h in the blood (Table 9 ). Cefuroxime represents a considerable advance in the cephalosporin area in having goodactivity against Harmophilus influenzre, including the f-lactamase producing, ampicillin resistant strains which have been encountered in the past 2-3 years, particularly in cases of meningitis (Williams & Cavanagh 1974 , Khan etal. 1974 . Cefuroxime is also highly active against Neisseria meningitidis and although it does not penetrate readily into the cerebrospinal fluid of uninfected experimental animals, there is some evidence that it is found in useful concentrations in human meningitis (Kuzemko 1977, personal communication) .
(4) Venereal infections: Unlike the earlier cephalosporins, cefuroxime has good activity against strains of Neisseria gonorrha?w. All penicillin sensitive strains were inhibited by 0.008 ,ug/ml. Recently, strains of this organism producing a TEM-like ,B-lactamase have been isolated from widely separated parts of the world (Roland et al. 1976 , Seeny & El Badri 1976 . Cefuroxime is also very active against these strains with an MIC of 0.08 ,ug/ml, because of its resistance to the enzyme. In low concentrations, it rapidly lyses growing cultures of N. gonorrh(eam whether they have a /-lactamase or not. These MICs are also exceeded in the serum for more than 8 h.
Cefuroxime has wide a spectrum ofantibacterial activity. This is due in part to its increased resistance to /-lactamases. In addition, cefuroxime readily penetrates Gram negative cells and thus does not require a steep concentration gradient between the tissue and infecting organisms to enable a lethal amount to penetrate the infecting bacterial cells. Cefuroxime protected laboratory animals against a variety of potentially lethal experimental infections at low doses. These included Staphylococcus aureus, E. coli, Proteus, Klebsiella, Enterobacter, H. influenza, and N. gonorrha-a. It is often assumed that an antibiotic will only be clinically effective if serum concentrations of at least twice the relevant MIC are maintained for several hours. However, cefuroxime protected small rodents against a variety of organisms at doses which gave peak serum levels that barely reached the MIC level, and then fell rapidly.
The infecting organisms were thus exposed to cefuroxime for a very short time, compared with the length of exposure in MIC tests. However, this was sufficient to avert the lethal outcome of infection in the living animals and clearly illustrates the difficulties encountered when attempts are made to correlate the static conditions of the MIC test with the much more complex and dynamic situation in the body. It appears that the much shorter contact time between organism and antibiotic may be more than counterbalanced by the effects of the body defence mechanisms.
The action of a number of antibiotics against Gram negative organisms is potentiated by serum proteins (Orsolini & Milani 1975) and this may partly account for a protective effect being obtained from doses which gave apparently ineffective antibiotic concentrations.
The pharmacokinetics of cefuroxime in man are much more favourable than those observed in the small rodents, and its MICs for many pathogens are exceeded for several hours in both serum and urine. It is therefore very likely that its excellent human pharmacokinetic properties, high metabolic stability, wide tissue distribution and low serum binding integrate very well with its high antibacterial activity and ,B-lactamase resistance. This gives promise that it will be therapeutically effective in a wide range of infections at relatively modest dose levels.
Summary
Cefuroxime is active in vitro against a wide range of pathogenic bacteria. In initial pharmacokinetic studies in man, intramuscular injections of 750 mg in solution gave peak serum concentrations which exceeded the MICs of such organisms several fold. The compound was metabolically stable and its ultimate half-life of 1.1 h allowed inhibitory concentrations to be maintained in the serum for several hours.
The present form of cefuroxime has a lower aqueous solubility, and it is convenient to use a suspension for intramuscular injection. It readily dissolves in a slightly larger volume of water for intravenous administration. Comparisons of the solution and suspension after intramuscular injection showed that their pharmacokinetic parameters were not significantly different.
In experimentally infected laboratory animals, 
